Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease

Abstract

Longitudinal increase of plasma pTau181 and glial fibrillary acidic protein (GFAP) can be measured in the preclinical phase of AD. Apolipoprotein E ε4 carriers experience faster increase in plasma pTau181 over time than non-carriers. Female sex showed accelerated increase in plasma GFAP over time compared to males. Aβ_42/40 and pTau231 values are already abnormal at baseline in individuals with both amyloid and tau PET burden.